[Trypanosome sensitivity to polyene antibiotics]

Antibiotiki
|June 1, 1982
PubMed

Insights

Polyenic antibiotics inhibit the growth of pathogenic Protozoa like Trypanosoma lewisi and Crithidia oncopelti by altering their cell membranes. Levorin and amphotericin B showed significant activity, reducing intracellular lipids.

Area of Science:

  • Microbiology
  • Parasitology
  • Biochemistry

Background:

  • Pathogenic Protozoa utilize plasma membrane swelling as a defense mechanism.
  • Polyenic antibiotics interact with membrane lipids, inducing structural changes in unicellular eukaryotes like fungi and Protozoa.

Purpose of the Study:

  • To investigate the inhibitory effects of five heptaene polyenic antibiotics on the growth of Trypanosoma lewisi and Crithidia oncopelti.
  • To determine the minimum inhibitory concentration (MIC) and IC50 values for these antibiotics.
  • To analyze the physiological, morphological, and lipid content changes in trypanosomides induced by these antibiotics.

Main Methods:

  • Cultivation of Trypanosoma lewisi and Crithidia oncopelti.
  • Determination of MIC and IC50 values for amphotericin B, mycoheptin, levorin, its sodium salt, and levoridone.
  • Microscopic examination for physiological and morphological changes.
  • Biochemical analysis of intracellular lipid content.

Main Results:

  • All tested polyenic antibiotics inhibited trypanosomide growth and development.
  • Levorin and amphotericin B exhibited the highest activity against Crithidia oncopelti, while levorin was most potent against Trypanosoma lewisi.
  • Significant physiological and morphological alterations were observed in the treated trypanosomides.
  • A reduction in total intracellular lipid content was demonstrated following antibiotic treatment.
  • The rate of inhibition varied based on the hydrophile structure of the antibiotic's lactone ring.

Conclusions:

  • Heptaene polyenic antibiotics are effective inhibitors of trypanosomide growth.
  • Levorin and amphotericin B show promise as potential therapeutic agents against these protozoan parasites.
  • Antibiotic-induced changes in membrane lipid composition are a key factor in their mechanism of action.
  • Structural modifications of polyenic antibiotics can influence their efficacy.

Related Concept Videos

Diversity of Protists I01:15

Diversity of Protists I

Excavata is a diverse group of protists that includes both chemoorganotrophic and phototrophic species, with some thriving in anaerobic environments. Among the key groups within Excavata are diplomonads and parabasalids, which are flagellated protists that lack mitochondria and chloroplasts. These microorganisms typically inhabit anoxic environments, such as the intestines of animals, where they exist either symbiotically or as parasites, relying on fermentation for energy production. Some...
American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...